UPC Analytics
ENDE
Overview · Filed: Nov 14, 2024

UPC_CFI_698/2024

METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Procedural & sub-applicationsDocument Access (RoP262)Milan CDGenericCase Closed
OverviewDecisionsCitationsDocumentsTimeline
Parties

Claimants

  • Accord Healthcare B.V.
  • Accord Healthcare S.L.U.
  • ACCORD HEALTHCARE LIMITED,
Reps: Phillip Rektorschek

Respondents

  • Novartis AG
Reps: Gregory Bacon (Bristows LLP); Wim Maas (Taylor Wessing N.V.)
Judges
  • Andrea Postiglione
  • Marije Knijff
  • Oliver Werner
Patents
  • EP2501384
CPC codes: A61P11/06, A61P37/06, A61P43/00, A61P17/00, A61P9/12, A61K31/506, A61P17/06, A61P19/02, A61P25/28, A61P35/00, A61K31/505, C07D239/69…

Sector: Organic Chemistry

Outcome
Dismissed
Filed: Nov 14, 2024
First decided: Feb 3, 2025
Language: English

Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP in the proceedings before the Milan Central Division was dismissed. The court found that STADAPHARM's primary purpose was to expose Novartis's defence strategy in order to facilitate a parallel national (Munich OLG) proceeding rather than to exercise legitimate public oversight. Access was denied as it would create undue pressure on Novartis and undermine the integrity of the proceedings. NOVARTIS's request for costs was also dismissed.

Open on UPC Registry